ASX:AGN Argenica Therapeutics (AGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argenica Therapeutics Stock (ASX:AGN) 30 days 90 days 365 days Advanced Chart Get Argenica Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$104.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia. Read More Receive AGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argenica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGN Stock News HeadlinesArgenica Therapeutics Issues New Shares Following Option ExerciseJuly 9, 2025 | tipranks.comArgenica Secures $1.5M Funding for Stroke Therapeutic TrialsJune 19, 2025 | tipranks.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Argenica Therapeutics to Host Investor Webinar on Phase 2 Stroke Trial ProgressMay 23, 2025 | msn.comASX Penny Stock Highlights For May 2025May 6, 2025 | uk.finance.yahoo.comArgenica Therapeutics Reports Reduced Losses Amid Increased R&D CostsFebruary 11, 2025 | tipranks.comArgenica Therapeutics Ltd Ordinary Shares AGNJanuary 10, 2024 | morningstar.comMHere's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn SituationJanuary 9, 2024 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryInsurance Current SymbolASX:AGN CIKN/A Webargenica.com.au Phone61 8 9329 3396FaxN/AEmployees22,300Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$5.48 million Net Margins-238.05% Pretax MarginN/A Return on Equity-60.20% Return on Assets-27.35% Debt Debt-to-Equity RatioN/A Current Ratio6.75 Quick Ratio12.21 Sales & Book Value Annual SalesA$2.60 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.13 per share Price / BookN/AMiscellaneous Outstanding Shares128,090,000Free FloatN/AMarket CapA$104.40 million OptionableNot Optionable Beta0.79 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:AGN) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argenica Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argenica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.